DLG4 and Alzheimer disease: In this AD model, Aβ25–35 oligomer administration significantly increased Aβ1–42 and pTau levels, as well as markers of astrogliosis, inflammation, LPO, and endoplasmic reticulum stress; meanwhile, Aβ25–35 oligomers reduced the levels of synaptic markers synaptophysin and PSD95 (Figure 2: p ≤ 0.001 compared with control mice).